http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1842537-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6572ff5df928fd17340eb2a8cb6d8502
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
filingDate 2007-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_230883e8fe89d2074751514cd6e0358d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa9cca417c3c138b3b24cb555bb4d4c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e94594cce3d90899d38a3c2aa6dc0b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1493b8caedbf37d6fc58ecfa3c22f50c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35f10a782c3b826056d476deab901363
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c360105e6ac108b009f79dc15b7e594
publicationDate 2007-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-1842537-A1
titleOfInvention Use of an anti-atherothrombotic compound for the manufacture of medicaments for the treatment of vascular disorders
abstract The present invention relates to the use of a specific thromboxane-prostaglandin (TP) receptor antagonist for the production of medicaments for the treatment of vascular disorders in patients with a history of stroke, particularly for the reduction of events. cerebrovascular and cardiovascular disease in patients with a history of ischemic stroke (CIA) or transient ischemic attack (TIA).
priorityDate 2006-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-4343776-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0648741-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005009428-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H08119936-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005032533-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395818
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226413560
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12444480
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2244
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127968075
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226413561
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226420681
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5333
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393693
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5560
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID114873
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226554173
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4737
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394110
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135433642
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60606
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226413167
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6385
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396698
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280497
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396699
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129772470
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9861403
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135440064
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129205760
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226487087
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135790204

Total number of triples: 56.